JP2012508170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508170A5 JP2012508170A5 JP2011534731A JP2011534731A JP2012508170A5 JP 2012508170 A5 JP2012508170 A5 JP 2012508170A5 JP 2011534731 A JP2011534731 A JP 2011534731A JP 2011534731 A JP2011534731 A JP 2011534731A JP 2012508170 A5 JP2012508170 A5 JP 2012508170A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- tgfβrii
- human
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19869708P | 2008-11-07 | 2008-11-07 | |
| US61/198,697 | 2008-11-07 | ||
| US17036909P | 2009-04-17 | 2009-04-17 | |
| US61/170,369 | 2009-04-17 | ||
| PCT/US2009/062450 WO2010053814A1 (en) | 2008-11-07 | 2009-10-29 | Anti-tgf-beta receptor ii antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508170A JP2012508170A (ja) | 2012-04-05 |
| JP2012508170A5 true JP2012508170A5 (https=) | 2014-04-24 |
| JP5667067B2 JP5667067B2 (ja) | 2015-02-12 |
Family
ID=41508691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534731A Expired - Fee Related JP5667067B2 (ja) | 2008-11-07 | 2009-10-29 | 抗ｔｇｆベータ受容体ｉｉ抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8147834B2 (https=) |
| EP (1) | EP2356152A1 (https=) |
| JP (1) | JP5667067B2 (https=) |
| KR (1) | KR101283856B1 (https=) |
| CN (1) | CN102209727B (https=) |
| AR (1) | AR073909A1 (https=) |
| AU (1) | AU2009311375B2 (https=) |
| BR (1) | BRPI0921263A2 (https=) |
| CA (1) | CA2742961C (https=) |
| EA (1) | EA025169B1 (https=) |
| IL (1) | IL211842A (https=) |
| JO (1) | JO3096B1 (https=) |
| MX (1) | MX2011004871A (https=) |
| NZ (1) | NZ591943A (https=) |
| PA (1) | PA8846101A1 (https=) |
| SG (1) | SG10201401280TA (https=) |
| TW (1) | TWI384998B (https=) |
| WO (1) | WO2010053814A1 (https=) |
| ZA (1) | ZA201103178B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6062375B2 (ja) | 2011-01-06 | 2017-01-18 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| JP7372728B2 (ja) | 2014-10-31 | 2023-11-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改変ｔ細胞に関する方法および組成物 |
| US10828353B2 (en) | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| EP3370768B9 (en) * | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| WO2017156500A1 (en) | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgfb1-binding immunoglobulins and use thereof |
| JP7632835B2 (ja) * | 2016-05-20 | 2025-02-19 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 加齢関連疾患及び症状の遺伝子治療法 |
| TW201825519A (zh) * | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| PE20191661A1 (es) * | 2017-01-06 | 2019-11-11 | Scholar Rock Inc | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos |
| CN106884005A (zh) * | 2017-01-19 | 2017-06-23 | 樊克兴 | 一种结直肠癌抗原特异性t细胞的制备方法 |
| WO2019084053A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| CA3079215A1 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
| CA3079897A1 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
| CN107973853B (zh) * | 2017-12-12 | 2021-04-30 | 山西农业大学 | 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN116199780A (zh) * | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
| KR102314157B1 (ko) * | 2020-01-10 | 2021-10-19 | 주식회사 뉴클릭스바이오 | TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법 |
| AU2022330896A1 (en) * | 2021-08-20 | 2024-02-22 | Akeso Biopharma, Inc. | FUSION PROTEIN CONTAINING ANTI-TIGIT ANTIBODY AND TGF-βR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| KR20250005109A (ko) * | 2022-04-15 | 2025-01-09 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-cd40 항체 및 이의 용도 |
| CN116178567B (zh) * | 2022-10-28 | 2025-01-28 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JP4124815B2 (ja) * | 1991-10-31 | 2008-07-23 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | ＴＧＦ−β型受容体ｃＤＮＡおよびその用途 |
| JP2001206899A (ja) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| JP2004121001A (ja) * | 2002-08-07 | 2004-04-22 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体 |
| EP1992360A4 (en) | 2006-02-01 | 2010-02-17 | Univ Tokyo | COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT |
-
2009
- 2009-10-18 JO JOP/2009/0382A patent/JO3096B1/ar active
- 2009-10-19 TW TW098135300A patent/TWI384998B/zh not_active IP Right Cessation
- 2009-10-19 AR ARP090104017A patent/AR073909A1/es unknown
- 2009-10-19 PA PA20098846101A patent/PA8846101A1/es unknown
- 2009-10-29 CN CN200980144391.1A patent/CN102209727B/zh not_active Expired - Fee Related
- 2009-10-29 US US12/608,034 patent/US8147834B2/en not_active Expired - Fee Related
- 2009-10-29 JP JP2011534731A patent/JP5667067B2/ja not_active Expired - Fee Related
- 2009-10-29 MX MX2011004871A patent/MX2011004871A/es active IP Right Grant
- 2009-10-29 KR KR1020117010399A patent/KR101283856B1/ko not_active Expired - Fee Related
- 2009-10-29 NZ NZ591943A patent/NZ591943A/xx not_active IP Right Cessation
- 2009-10-29 BR BRPI0921263-9A patent/BRPI0921263A2/pt not_active IP Right Cessation
- 2009-10-29 CA CA2742961A patent/CA2742961C/en not_active Expired - Fee Related
- 2009-10-29 EA EA201170659A patent/EA025169B1/ru not_active IP Right Cessation
- 2009-10-29 EP EP09745224A patent/EP2356152A1/en not_active Withdrawn
- 2009-10-29 AU AU2009311375A patent/AU2009311375B2/en not_active Ceased
- 2009-10-29 SG SG10201401280TA patent/SG10201401280TA/en unknown
- 2009-10-29 WO PCT/US2009/062450 patent/WO2010053814A1/en not_active Ceased
-
2011
- 2011-03-21 IL IL211842A patent/IL211842A/en not_active IP Right Cessation
- 2011-04-29 ZA ZA2011/03178A patent/ZA201103178B/en unknown
-
2012
- 2012-02-20 US US13/400,308 patent/US20120177666A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5667067B2 (ja) | 抗ｔｇｆベータ受容体ｉｉ抗体 | |
| JP2012508170A5 (https=) | ||
| JP7273110B2 (ja) | 高親和性抗ｖｅｇｆ抗体 | |
| CN101102791B (zh) | 抗血管内皮生长因子受体-1的抗体 | |
| CN117098561A (zh) | Ccr8抗体及其应用 | |
| JP2021508676A (ja) | 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用 | |
| CN105829345B (zh) | 结合egfr和met的多功能抗体 | |
| KR20210142638A (ko) | Cd3 항원 결합 단편 및 이의 응용 | |
| JP6925981B2 (ja) | Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体 | |
| KR20220082007A (ko) | 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도 | |
| WO2022068810A1 (zh) | 抗Claudin18.2和CD3的双特异性抗体以及其用途 | |
| CN114786722A (zh) | 抗类趋化因子受体1人源化抗体及其治疗应用 | |
| TWI413527B (zh) | 抗ｖｅｇｆｒ－３抗體組合物 | |
| WO2022237819A1 (zh) | 抗Siglec-15抗体及其用途 | |
| EP3777889A1 (en) | Use of probdnf regulator in b cell-related diseases | |
| CA2762446A1 (en) | Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis | |
| CN113166264B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| CN113164601B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| KR20240022546A (ko) | 항il-36r 항체 및 그의 사용 | |
| CN118580373A (zh) | 一种TGF-β和TIGIT双特异性融合蛋白及其用途 | |
| CN115515637A (zh) | 使用il-20拮抗剂和免疫检查点抑制剂的混合式治疗 | |
| HK1167325B (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| HK1115302B (en) | Antibodies against vascular endothelial growth factor receptor-1 |